BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37558687)

  • 1. Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid.
    Lennartz M; Csomós H; Chirico V; Weidemann S; Gorbokon N; Menz A; Büscheck F; Hube-Magg C; Höflmayer D; Bernreuther C; Blessin NC; Lebok P; Sauter G; Steurer S; Burandt E; Dum D; Krech T; Simon R; Minner S; Jacobsen F; Clauditz TS; Luebke AM; Siraj AK; Al-Dayel F; Al-Kuraya KS; Hinsch A
    Sci Rep; 2023 Aug; 13(1):12917. PubMed ID: 37558687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16.
    Lennartz M; Csomós H; Bernreuther C; Büscheck F; Fraune C; Simon R; Sauter G; Steurer S; Eichenauer T; Dahlem R; Fisch M; Riechardt S; Rink M; Minner S; Höflmayer D
    Urol Oncol; 2022 Jul; 40(7):348.e1-348.e8. PubMed ID: 35606285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDH16/Ksp-cadherin is expressed in the developing thyroid gland and is strongly down-regulated in thyroid carcinomas.
    Calì G; Gentile F; Mogavero S; Pallante P; Nitsch R; Ciancia G; Ferraro A; Fusco A; Nitsch L
    Endocrinology; 2012 Jan; 153(1):522-34. PubMed ID: 22028439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.
    Kuehn A; Paner GP; Skinnider BF; Cohen C; Datta MW; Young AN; Srigley JR; Amin MB
    Am J Surg Pathol; 2007 Oct; 31(10):1528-33. PubMed ID: 17895753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.
    Siraj AK; Parvathareddy SK; Al-Rasheed M; Annaiyappanaidu P; Siraj N; Lennartz M; Al-Sobhi SS; Al-Dayel F; Sauter G; Al-Kuraya KS
    Sci Rep; 2023 Oct; 13(1):18559. PubMed ID: 37899424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
    Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
    Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
    Tretiakova MS; Sahoo S; Takahashi M; Turkyilmaz M; Vogelzang NJ; Lin F; Krausz T; Teh BT; Yang XJ
    Am J Surg Pathol; 2004 Jan; 28(1):69-76. PubMed ID: 14707866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.
    Nonaka D; Tang Y; Chiriboga L; Rivera M; Ghossein R
    Mod Pathol; 2008 Feb; 21(2):192-200. PubMed ID: 18084247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can CD10 be used as a diagnostic marker in thyroid pathology?
    Yegen G; Demir MA; Ertan Y; Nalbant OA; Tunçyürek M
    Virchows Arch; 2009 Jan; 454(1):101-5. PubMed ID: 19031085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma.
    Mazal PR; Exner M; Haitel A; Krieger S; Thomson RB; Aronson PS; Susani M
    Hum Pathol; 2005 Jan; 36(1):22-8. PubMed ID: 15712178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
    Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
    Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].
    Guyétant S; Michalak S; Valo I; Saint-André JP
    Ann Pathol; 2003 Feb; 23(1):11-20. PubMed ID: 12743496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis.
    Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Luo M; Zhan S; Xie K; Ma Y; Li QQ
    Int J Biol Markers; 2010; 25(1):38-45. PubMed ID: 20306451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
    Osunkoya AO; Yin-Goen Q; Phan JH; Moffitt RA; Stokes TH; Wang MD; Young AN
    Hum Pathol; 2009 Dec; 40(12):1671-8. PubMed ID: 19695674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases.
    Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
    Mod Pathol; 2004 Feb; 17(2):180-8. PubMed ID: 14657952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
    Pyo JS; Kim DH; Yang J
    Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray.
    Patel MR; Bryson PC; Shores CG; Hart CF; Thorne LB; Deal AM; Zanation AM
    Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):590-6. PubMed ID: 19528408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
    Sharma SG; Gokden M; McKenney JK; Phan DC; Cox RM; Kelly T; Gokden N
    Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):494-8. PubMed ID: 21102195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.